These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 38619393

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.
    Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, Ghanekar A, Lilly L, Cattral M, Galvin Z, Selzner M, Bhat M, Selzner N, McGilvray I, Greig PD, Grant DR, Sapisochin G.
    J Hepatol; 2019 Apr; 70(4):666-673. PubMed ID: 30630009
    [Abstract] [Full Text] [Related]

  • 3. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases--an analysis of the UNOS database.
    Kashyap R, Safadjou S, Chen R, Mantry P, Sharma R, Patil V, Maloo M, Ryan C, Marroquin C, Barry C, Ramaraju G, Maliakkal B, Orloff M.
    J Gastrointest Surg; 2010 Sep; 14(9):1362-9. PubMed ID: 20617395
    [Abstract] [Full Text] [Related]

  • 4. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD, Goldberg DS, Goodrich NP, Lok AS, Verna EC, Selzner N, Stravitz RT, Merion RM.
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of Survival Benefits of Living Versus Deceased Donor Liver Transplant in High Model for End-Stage Liver Disease and Hepatorenal Syndrome.
    Wong TC, Fung JY, Pang HH, Leung CK, Li HF, Sin SL, Ma KW, She BW, Dai JW, Chan AC, Cheung TT, Lo CM.
    Hepatology; 2021 Jun; 73(6):2441-2454. PubMed ID: 33006772
    [Abstract] [Full Text] [Related]

  • 7. Clinical analysis of liver transplantation in autoimmune liver diseases.
    Zhong CP, Xi ZF, Xia Q.
    Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):27-31. PubMed ID: 29428100
    [Abstract] [Full Text] [Related]

  • 8. Living Donor Availability Improves Patient Survival in a North American Center: An Intention-to-treat Analysis.
    Li Z, Jones O, Magyar CTJ, Claasen MPAW, Ivanics T, Choi WJ, Rajendran L, Winter E, Bucur R, Rukavina N, Jaeckel E, Selzner N, Sayed BA, Ghanekar A, Cattral M, Sapisochin G.
    Ann Surg; 2024 Jul 23. PubMed ID: 39041223
    [Abstract] [Full Text] [Related]

  • 9. Long-term Outcomes and Risk Factors After Adult Living Donor Liver Transplantation.
    Imai D, Yoshizumi T, Sakata K, Ikegami T, Itoh S, Harada N, Motomura T, Toshima T, Mano Y, Soejima Y, Maehara Y.
    Transplantation; 2018 Sep 23; 102(9):e382-e391. PubMed ID: 29912047
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant.
    Lai Q, Sapisochin G, Gorgen A, Vitale A, Halazun KJ, Iesari S, Schaefer B, Bhangui P, Mennini G, Wong TCL, Uemoto S, Lin CC, Mittler J, Ikegami T, Yang Z, Frigo AC, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut JP.
    JAMA Surg; 2021 Sep 01; 156(9):e213112. PubMed ID: 34259797
    [Abstract] [Full Text] [Related]

  • 11. Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy.
    Staufer K, Kivaranovic D, Rasoul-Rockenschaub S, Soliman T, Trauner M, Berlakovich G.
    HPB (Oxford); 2018 Oct 01; 20(10):916-924. PubMed ID: 29937419
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses.
    Wong TCL, Ng KKC, Fung JYY, Chan AAC, Cheung TT, Chok KSH, Dai JWC, Lo CM.
    Ann Surg Oncol; 2019 May 01; 26(5):1454-1462. PubMed ID: 30737669
    [Abstract] [Full Text] [Related]

  • 14. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
    Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE.
    Hepatology; 2011 Oct 01; 54(4):1313-21. PubMed ID: 21688284
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An updated analysis of retransplantation following living donor liver transplantation in the United States: Insights from the latest UNOS database.
    Akabane M, Imaoka Y, Esquivel CO, Sasaki K.
    Liver Transpl; 2024 Sep 01; 30(9):887-895. PubMed ID: 38727618
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis.
    Patel YA, Henson JB, Wilder JM, Zheng J, Chow SC, Berg CL, Knechtle SJ, Muir AJ.
    Clin Transplant; 2018 Oct 01; 32(10):e13388. PubMed ID: 30136315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.